Teja Kulkarni
@tkulkarni.bsky.social
#PulmCC Physician Scientist #uabmedicine| Director #UAB-ILD program #curePF|#HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine
Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.
April 14, 2025 at 9:05 PM
Had the same question when I saw this paper- typically co-manage SSc patients with our rheumatology colleagues and ILD team are predominant prescribers for Nintedanib.
Reposted by Teja Kulkarni
Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?
March 3, 2025 at 9:27 PM
Exactly. Think about it - what if this drug improves FVC - what would the patients’ risk tolerance be?
Hope so! Especially since there seems to be an efficacy signal.
March 3, 2025 at 7:06 PM
Hope so! Especially since there seems to be an efficacy signal.
👆I feel like if it is used responsibly to aid with language (and not the underlying science), there might be precedence to allow it- wouldn’t it be easy to implement this though.
November 27, 2024 at 11:46 PM
👆I feel like if it is used responsibly to aid with language (and not the underlying science), there might be precedence to allow it- wouldn’t it be easy to implement this though.
👋 I'm a pulmonary critical care physician and ILD specialist at UAB. Within ATS, I'm active in the Clinical Problems Assembly!
November 23, 2024 at 1:17 AM
👋 I'm a pulmonary critical care physician and ILD specialist at UAB. Within ATS, I'm active in the Clinical Problems Assembly!